Scott Gottlieb
Mark B. McClellan
Two former FDA commissioners—Scott Gottlieb and , Mark B. McClellan—
How is the enterprise of cancer research doing after the first 100 days of the Trump administration?
Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.
In a statement issued on May 1, NIH said it’s immediately halting most new grant awards to foreign partners working in US-led research consortia.
FDA announced a meeting of the Oncologic Drugs Advisory Committee May 20 and 21. It will be the first ODAC meeting since President Trump was inaugurated.
President Trump nominated Casey Means as the U.S. surgeon general. Means, a wellness influencer, has “impeccable ‘MAHA’ credentials,” Trump wrote in a post on X.
FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.
